RECORD // Company

Kiora Pharmaceuticals Inc

Formerly: EYEGATE PHARMACEUTICALS INC

Built 2026-11-22T04:29:54Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Records under a former name (3)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (3)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Kiora Pharmaceuticals, Inc. · Ctgov · same registered legal name as 'KIORA PHARMACEUTICALS INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • KIORA PHARMACEUTICALS · Epa echo · exact name match to 'KIORA PHARMACEUTICALS INC' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • KIORA PHARMACEUTICALS · Epa rcra · exact name match to 'KIORA PHARMACEUTICALS INC' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare

4 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001372514-26-000092

ItemValuePeriodFormFiledAccessionReport
Revenue$1,000,0003 months ended 2026-09-3010-Q2026-11-120001372514-26-0000922026-11-22 04:29 UTCReport an error
Net income (loss)$-1,749,5213 months ended 2026-09-3010-Q2026-11-120001372514-26-0000922026-11-22 04:29 UTCReport an error
Cash and cash equivalents$5,570,640at 2026-09-3010-Q2026-11-120001372514-26-0000922026-11-22 04:29 UTCReport an error
Contract liabilities, noncurrent$1,250,000at 2026-09-3010-Q2026-11-120001372514-26-0000922026-11-22 04:29 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001372514
Ticker
KPRX
EIN
980443284
CUSIP
49721T507
Record ID
sx:sec:0001372514

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

35 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 04:29 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-22 04:29 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-22 04:29 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 04:29 UTCReport an error
Business address169 SAXONY RD., SUITE 212, ENCINITAS, CA, 920242026-11-16SEC EDGAR company profile2026-11-22 04:29 UTCReport an error
ExchangesNasdaq, OTC2026-11-16SEC EDGAR company profile2026-11-22 04:29 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$02025-12-3110-K, XBRL Revenues2026-11-22 04:29 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-10,835,1542025-12-3110-K, XBRL NetIncomeLoss2026-11-22 04:29 UTCReport an error
Total assets (at 2025-12-31)$24,253,3002025-12-3110-K, XBRL Assets2026-11-22 04:29 UTCReport an error
Stockholders' equity (at 2025-12-31)$16,126,5362025-12-3110-K, XBRL StockholdersEquity2026-11-22 04:29 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$8,696,5702025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 04:29 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-9,961,1762025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 04:29 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$110,7892025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 04:29 UTCReport an error
Operating lease liabilities (at 2025-12-31)$368,2592025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 04:29 UTCReport an error
Form D total offering amount (D filed 2026-04-21)$5,000,0002026-04-21D2026-11-22 04:29 UTCReport an error
Form D total amount sold (D filed 2026-04-21)$5,000,0002026-04-21D2026-11-22 04:29 UTCReport an error
Form D industry groupPharmaceuticals2026-04-21D2026-11-22 04:29 UTCReport an error
Form D revenue rangeDecline to Disclose2026-04-21D2026-11-22 04:29 UTCReport an error
Form D date of first sale2026-04-062026-04-21D2026-11-22 04:29 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Conditions (filed 2026-11-12)On November 12, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended September 30, 2026 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. This information will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates them by reference.2026-11-12SEC EDGAR 8-K 0001372514-26-000093 (text as filed, excerpt)2026-11-22 04:29 UTCReport an error
8-K Item 1.01, Entry Into a Material Definitive Agreement (filed 2026-10-29)On October 23, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) entered into an Exclusive License Agreement (the “Agreement”) with Senju Pharmaceutical Co., Ltd. (“Senju”) to license a late-stage neuroprotective, oral small-molecule calpain inhibitor (“KIO-401”). Under the Agreement, which has an effective date of October 5, 2026, Senju granted the Company an exclusive, sublicensable license to develop, manufacture, commercialize, and otherwise exploit KIO-401 throughout the world except for certain specified countries, including countries in Asia (the “Territory”), to develop and commercialize a companion diagnostic tool for glaucoma in the Territory, and to file for regulatory approvals…2026-10-29SEC EDGAR 8-K 0001372514-26-000088 (text as filed, excerpt)2026-11-22 04:29 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-29)On October 29, 2026, the Company issued a press release announcing the signing of the Agreement with Senju. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. Also on October 29, 2026, the Company posted an investor presentation, which may be accessed through the Company’s investor relations website. A copy of the presentation is furnished herewith as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein. The Company intends to use this presentation in meetings with analysts, investors and others from time to time. The information furnished under this Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall…2026-10-29SEC EDGAR 8-K 0001372514-26-000088 (text as filed, excerpt)2026-11-22 04:29 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-09-08)On September 8, 2026, the Company issued a press release announcing the hiring of Mr. Lane, a copy of which is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.2026-09-08SEC EDGAR 8-K 0001372514-26-000079 (text as filed, excerpt)2026-11-22 04:29 UTCReport an error
8-K Item 1.01, Entry Into a Material Definitive Agreement (filed 2026-08-19)License Agreement Effective August 20, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) entered into an Exclusive License and Development Agreement (the “Agreement”) with Chong Jun Dang Pharmaceutical Corporation (“CKD”) with respect to the Company’s KIO-301 molecular photoswitch product (the “Product”). Under the Agreement, the Company granted to CKD an exclusive, sublicensable license to develop, manufacture, commercialize, and file for regulatory approvals with respect to the Product in South Korea (the “Territory”) for use in the field of retinitis pigmentosa and/or any other disease in ophthalmology (the “Field”). CKD will be responsible for development and commercialization…2026-08-19SEC EDGAR 8-K 0001372514-26-000077 (text as filed, excerpt)2026-11-22 04:29 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-08-19)On August 19, 2026, the Company issued a press release announcing the signing of the Agreement with CKD (the “August 19, 2026 Press Release”). A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be…2026-08-19SEC EDGAR 8-K 0001372514-26-000077 (text as filed, excerpt)2026-11-22 04:29 UTCReport an error
Largest institutional holder #1 (13F as filed): PERCEPTIVE ADVISORS LLC$1,153,1792026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:29 UTCReport an error
Largest institutional holder #2 (13F as filed): ADAR1 Capital Management, LLC$441,6852026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:29 UTCReport an error
Largest institutional holder #3 (13F as filed): CITADEL ADVISORS LLC$305,1092026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:29 UTCReport an error
Largest institutional holder #4 (13F as filed): TWO SIGMA INVESTMENTS, LP$233,5232026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:29 UTCReport an error
Largest institutional holder #5 (13F as filed): MILLENNIUM MANAGEMENT LLC$195,1512026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:29 UTCReport an error
Largest institutional holder #6 (13F as filed): RENAISSANCE TECHNOLOGIES LLC$78,4372026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:29 UTCReport an error
Largest institutional holder #7 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$70,2642026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:29 UTCReport an error
Largest institutional holder #8 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$52,2342026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:29 UTCReport an error
Largest institutional holder #9 (13F as filed): Scientech Research LLC$49,3022026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:29 UTCReport an error
Largest institutional holder #10 (13F as filed): VANGUARD FIDUCIARY TRUST CO$34,2692026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:29 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.